Drug intelligence / Profile preview

deslorelin + estradiol + medroxyprogesterone acetate + testosterone

Development stage: Unknown
Lead developer: Balance Pharmaceuticals
Modality: Small Molecules
Administration: Intranasal, Transdermal

Overview

A combination therapy consisting of the gonadotropin-releasing hormone agonist (GnRHa) deslorelin with add-back hormones estradiol, medroxyprogesterone acetate, and testosterone. This combination has been studied for the treatment of endometriosis-related pelvic pain. The GnRHa component (deslorelin) suppresses ovarian production of hormones, while the add-back hormones help minimize hypoestrogenic side effects such as bone mineral density loss and hot flashes that would typically occur with GnRHa therapy alone.

Targets

AR (Adrenergic receptors)ER (Estrogen receptor)GnRHR (Gonadotropin-releasing hormone receptor)PR (Progesterone receptor)

Beyond the preview

Go deeper on deslorelin + estradiol + medroxyprogesterone acetate + testosterone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on deslorelin + estradiol + medroxyprogesterone acetate + testosterone.